摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4E)-6-甲基-4-庚烯-2-酮 | 104728-05-4

中文名称
(4E)-6-甲基-4-庚烯-2-酮
中文别名
——
英文名称
(E)-6-methyl-4-hepten-2-one
英文别名
6-methyl-hept-4-en-2-one;6-Methyl-hept-4-en-2-on;β-Isomethylheptenon;4-Hepten-2-one, 6-methyl-;(E)-6-methylhept-4-en-2-one
(4E)-6-甲基-4-庚烯-2-酮化学式
CAS
104728-05-4
化学式
C8H14O
mdl
——
分子量
126.199
InChiKey
UURQIFMXMISCGV-SNAWJCMRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2914190090

SDS

SDS:bec48a15b8088ad0894d05691e62af90
查看

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Wallach, Justus Liebigs Annalen der Chemie, 1911, vol. 381, p. 85
    摘要:
    DOI:
  • 作为产物:
    描述:
    6-甲基庚-3-炔-2-醇 以3%的产率得到
    参考文献:
    名称:
    MA, DAWEI;LU, XIYAN, TETRAHEDRON LETT., 30,(1989) N6, C. 2109-2112
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Isomerization of propargylic alcohols catalyzed by an iridium complex
    作者:Dawei Ma、Xiyan Lu
    DOI:10.1016/s0040-4039(01)93725-6
    日期:1989.1
    α,β-Enones were synthesized by the isomerization of propargylic alcohols catalyzed by an iridium pentahydride complex.
    通过五氢化铱配合物催化的炔丙醇的异构化反应合成了α,β-烯酮。
  • Method for preparing an unsaturated carboxylic acid
    申请人:Jacquot Roland
    公开号:US20060100459A1
    公开(公告)日:2006-05-11
    The invention concerns a method for preparing an unsaturated carboxylic acid from the corresponding aldehyde. More particularly, the invention aims at preparing an aliphatic carboxylic acid having at least an unsaturation conjugated with the carbonyl group. In particular, the invention concerns the preparation of geranic acid. The invention relates to a method for preparing an unsaturated carboxylic acid from the corresponding aldehyde. Said method is characterized in that it comprises a step which consists in oxidizing said aldehyde, in controlled basic medium and using molecular oxygen or a gas containing same, in the presence of a catalyst based on palladium and/or platinum and an activator based on bismuth, in conditions such that the oxidizing is carried out by diffusion process
    这项发明涉及一种从相应的醛制备不饱和羧酸的方法。更具体地说,该发明旨在制备至少具有与羰基共轭的不饱和的脂肪族羧酸。特别是,该发明涉及葛兰酸的制备。该发明涉及一种从相应醛制备不饱和羧酸的方法。所述方法的特征在于,它包括一步,即在受控的碱性介质中,使用分子氧或含有分子氧的气体,在钯和/或铂基催化剂和基于铋的活化剂的存在下,以扩散过程进行氧化所述醛的步骤进行。
  • AMINOTHIAZOLES AND THEIR USES
    申请人:Bushell Simon
    公开号:US20140315790A1
    公开(公告)日:2014-10-23
    The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
    本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
  • Palladium catalyzed reductive decarboxylation of allyl α-alkenyl-β-ketoesters. A new synthesis of (E)-3-alkenones
    作者:Valentine Ragoussis、Alexandros Giannikopoulos
    DOI:10.1016/j.tetlet.2005.11.122
    日期:2006.1
    The reductive decarboxylation of α-alkenyl derivatives of allyl-β-ketoesters was achieved by use of palladium(0) catalyst generated in situ from Pd(OAc)2 and PPh3, with triethylammonium formate as the hydride source, in THF. The reaction proceeds smoothly and cleanly, with linear alkenyl derivatives of allyl-β-ketoesters, to afford (E)-3-alkenones in good to excellent yields (73–92%) and high stereoselectivity
    烯丙基-β-酮酸酯的α-烯基衍生物的还原脱羧反应是通过使用由Pd(OAc)2和PPh 3原位生成的钯(0)催化剂,以甲酸三乙铵为氢化物源,在THF中实现的。该反应可与烯丙基-β-酮酸酯的线性烯基衍生物平稳且清洁地进行,以良好至极佳的收率(73–92%)和高的立体选择性(> 98%)提供(E)-3-烯酮。
  • INHIBITORS OF TYROSINE KINASES AND USES THEREOF
    申请人:JANKOWSKI Orion D.
    公开号:US20100035841A1
    公开(公告)日:2010-02-11
    Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.
    本文公开了抑制特定酪氨酸激酶活性的化合物。公开了制备这些化合物的方法。还公开了包括这些化合物的药物组合物。提供了使用所述化合物单独或与其他治疗剂联合治疗酪氨酸激酶介导的疾病或病症或酪氨酸激酶依赖性疾病或病症的方法。
查看更多